Biogen Inc. (BIIB34.SA) Stock Price, News & Chart

	BIIB34.SA	AMGN	BMY	NVS	SNW.F	LLY
Market cap	204.90B	258.68B	131.21B	311.59B	100.84B	1.26T
P/E (TTM)	115.1	27.7	14.2	31.5	24.3	46.0
Forward P/E	—	19.5	9.6	16.6	9.7	28.3
Price/book	2.1	18.0	5.6	8.4	1.4	31.4
Dividend yield	—	2.11%	3.93%	2.87%	5.11%	0.49%
1-year change	+62.15%	+51.61%	+37.66%	+30.35%	−2.66%	+51.26%
Today	+0.48%	+3.73%	+4.02%	+3.59%	+0.89%	+0.61%

Market cap

204.90B

258.68B

131.21B

311.59B

100.84B

1.26T

P/E (TTM)

115.1

27.7

14.2

31.5

24.3

46.0

Forward P/E

—

19.5

9.6

16.6

9.7

28.3

Price/book

2.1

18.0

5.6

8.4

1.4

31.4

Dividend yield

—

2.11%

3.93%

2.87%

5.11%

0.49%

1-year change

+62.15%

+51.61%

+37.66%

+30.35%

−2.66%

+51.26%

Today

+0.48%

+3.73%

+4.02%

+3.59%

+0.89%

+0.61%

Company	Mkt cap	Price	Today
Amgen Inc.AMGN · Drug Manufacturers - General	258.68B	478.48	+3.73%
Bristol-Myers Squibb CompanyBMY · Drug Manufacturers - General	131.21B	64.19	+4.02%
Novartis AGNVS · Drug Manufacturers - General	311.59B	164.98	+3.59%
SanofiSNW.F · Drug Manufacturers - General	100.84B	84.17	+0.89%
Eli Lilly and CompanyLLY · Drug Manufacturers - General Odds	1.26T	1,417.99	+0.61%
AbbVie Inc.0QCV.IL · Drug Manufacturers - General	536.09B	298.00	+4.93%
Roivant Sciences Ltd.ROIV · Biotechnology	27.61B	38.23	+6.08%
BioArctic AB (publ)B9A.F · Biotechnology	2.45B	27.58	−0.29%

Company	Mkt cap	Price	Today
Pfizer Inc.PFE · New York, NY Odds	175.50B	30.79	+2.63%
Novo Nordisk A/SNVO · Bagsvaerd, Denmark	185.98B	42.18	+4.95%
Gilead Sciences, Inc.GILD · Foster City, CA Odds	216.41B	174.48	+4.19%
AstraZeneca PLCAZN.L · Cambridge, United Kingdom	217.84B	14,046.00	+0.16%
Marksans Pharma LimitedMARKSANS.BO · Mumbai, India	142.25B	313.65	+4.15%
Bristol-Myers Squibb CompanyBMY · Princeton, NJ	131.21B	64.19	+4.02%
Amgen Inc.AMGN · Thousand Oaks, CA	258.68B	478.48	+3.73%
Novartis AGNOTA.F · Basel, Switzerland	271.96B	144.00	0.00%

Company	Mkt cap	Price	Today
Yungjin Pharm. Co., Ltd.003520.KS · Drug Manufacturers - Specialty & Generic	155.64B	851.00	−3.30%
Pfizer Inc.PFE · Drug Manufacturers - General Odds	175.50B	30.79	+2.63%
Towa Pharmaceutical Co., Ltd.4553.T · Drug Manufacturers - Specialty & Generic	179.68B	3,650.00	+3.84%
DAE HWA Pharmaceutical Co., Ltd.067080.KQ · Drug Manufacturers - Specialty & Generic	169.30B	9,190.00	−0.11%
AS ONE Corporation7476.T · Medical Distribution	185.22B	2,597.00	+4.80%
Swedish Orphan Biovitrum AB (publ)0MTD.IL · Drug Manufacturers - Specialty & Generic	178.69B	493.90	+2.36%
Caplin Point Laboratories LimitedCAPLIPOINT.NS · Drug Manufacturers - Specialty & Generic	184.05B	2,421.40	+0.22%
Novo Nordisk A/SNVO · Drug Manufacturers - General	185.98B	42.18	+4.95%

Company	Mkt cap	Price	Today
Moderna, Inc.MRNA · Cambridge, MA Odds	103.15B	258.38	+13.11%
Akamai Technologies, Inc.AKAM · Cambridge, MA Odds	12.35B	85.93	−0.69%
GE Vernova Inc.GEV · Cambridge, MA	220.43B	832.83	−9.30%
Alnylam Pharmaceuticals, Inc.ALNY · Cambridge, MA Odds	21.57B	161.08	+0.74%
HubSpot, Inc.HUBS · Cambridge, MA	11.09B	216.64	−4.21%
Nuvalent IncNUVL · Cambridge, MA	9.81B	123.96	0.00%
Scholar Rock Holding CorporationSRRK · Cambridge, MA	5.61B	46.09	+4.80%
Relay Therapeutics, Inc.RLAY · Cambridge, MA	3.95B	18.03	+3.38%

Company	Mkt cap	Price	Today
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.600436.SS · Correlation 0.34	81.65B	135.33	+2.39%

Company	Mkt cap	Price	Today
GILEADGILD34.SA	1.19T	79.85	+3.33%
AMGENAMGN34.SA	1.42T	93.78	+3.49%
PFIZERPFIZ34.SA	953.24B	41.81	+1.38%
MERCKMRCK34.SA	2.05T	103.62	+5.02%
JOHNSONJNJB34.SA	3.62T	100.38	+3.45%

Longevity.Technology·21h agoNegative

Biogen’s tau drug diranersen gets a CTAD spotlight

Alzheimer’s research has spent decades on amyloid, the sticky protein that clumps between brain cells. Tau is the other suspect, and it gets less of the glory. Biogen plans to change that a little this month. The company will present new…

BIIB GOOGL

openPR.com·1d ago

Cutaneous Lupus Erythematosus Pipeline Analysis 2026: Phase III and Phase II Assets, MOA Breakdown, and ROA Trends | Biogen, Horizon Therapeutics, Bristol-Myers Squibb, AstraZeneca, Sanofi, Amgen

Albany New York November 03 2026 As per DelveInsight s assessment globally Cutaneous Lupus Erythematosus pipeline constitutes 8 key companies continuously working towards developing 10 Cutaneous Lupus Erythematosus treatment therapies…

BIIB

CMC Markets·Oct 27Negative

BIIB Stock Earnings Preview: What’s Next for Biogen as its MS Business Wanes?

69% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider. You should consider whether you can afford to take the high risk of losing your money. 27 Oct 2026, 15:30 Biogen [BIIB] is a…

BIIB LLY VRTX

InvestyWise·1d agoNegative

Biogen Pharmachem Industries reports profit of ₹25.73 crore for Q2 2026

Biogen Pharmachem reports ₹25.73 lakh Q2 profit InvestyWise Biogen Pharmachem Industries reports profit of ₹25.73 crore for Q2 2026 Biogen Pharmachem Industries Limited has announced its unaudited financial results for the quarter and…

BIIB BMRN

FinancialContent·Oct 12Positive

Biogen (BIIB) Stock Is Up, What You Need To Know

Shares of biotech company Biogen (NASDAQ:BIIB) jumped 3.5% in the pre-market session after JPMorgan upgraded the stock to Overweight from Neutral with a $300 price target, raised from $210. As detailed by Investing.com, Schott observed in…

BIIB GILD AMGN ABBV

@kalkineus·2d agoPositive

Biogen's Jane Grogan Executes 695 RSU Conversion and Tax Withholding on October 30, 2026

Is Southern Company (NYSE:SO) Powering the AI Boom? Are AI Agents Lifting Salesforce (NYSE:CRM)? Is Adobe (NASDAQ:ADBE) Winning With Generative AI? Is Cisco (NASDAQ:CSCO) Plugging Into AI Demand? On November 2, 2026, Jane Grogan, Head of…

URGN GEN

Longevity.Technology·6d agoPositive

Biogen to share long-term trial results for its Alzheimer’s drugs

Biogen will present new data across its Alzheimer’s disease portfolio at the 19th Clinical Trials on Alzheimer’s Disease conference, 16–19 November 2026, in Boston. Presentations will include expanded results from the Phase 2 CELIA study…

BIIB

TradingView·Oct 28Positive

Biogen Q3 Revenue Rises 11% to $2.8 Billion; Raises EPS Guidance

TradingView Biogen Q3 Revenue Rises 11% to $2.8 Billion; Raises EPS Guidance Biogen reported third-quarter 2026 revenue of $2.8 billion, up 11% year over year, and non-GAAP diluted EPS of $2.62. GAAP results included a net loss of $20

BIIB PFE BMRN

The Globe and Mail·5d agoNegative

Stifel Nicolaus Sticks to Their Buy Rating for Biogen (BIIB)

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Biogen yesterday and set a price target of $286.00. Matteis covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Contineum Therapeutics, Inc. Class A, and…

BIIB BCS

The Globe and Mail·5d agoNegative

Biogen (BIIB) Receives a Buy from Needham

In a report released today, Ami Fadia from Needham reiterated a Buy rating on Biogen, with a price target of $290.00. According to TipRanks, Fadia is a 5-star analyst with an average return of 30.0% and a 54.46% success rate. Fadia covers…

BIIB BCS PFE

Days on the list

30 d

1 yr

Best

Trending

—

Install

Biogen Inc.

Key statistics

Against its peers

Latest news